Alert detail
LCD L38047: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies — Palmetto GBA
What changed
NGS LDT coverage criteria for myeloid malignancies in JJ/JM jurisdictions.
Who’s affected: Oncology billing teams · Effective: March 28, 2024
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 10 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.